Exscientia CEO Andrew Hopkins and Sanofi CEO Paul Hudson
January 7, 2022 01:01 AM ESTUpdated 09:20 AM
Deals
R&D

Sanofi, Ex­sci­en­tia ink the next AI megadeal, sign­ing terms on a $100M up­front pact with up to 15 drugs on the line

Kyle Blankenship

Drug R&D has for years had an abysmal track record of suc­cess, with the vast ma­jor­i­ty of drug can­di­dates nev­er mak­ing it to mar­ket. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times